| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥121.8B | ¥116.3B | +4.8% |
| Operating Income | ¥10.1B | ¥9.2B | +10.3% |
| Ordinary Income | ¥9.9B | ¥9.2B | +8.3% |
| Net Income | ¥6.8B | ¥6.3B | +7.7% |
| ROE | 12.0% | 18.3% | - |
FY2026 Q3 results: Revenue 121.8B yen (YoY +4.8%), Operating Income 10.1B yen (+10.3%), Ordinary Income 9.9B yen (+8.3%), and Net Income 6.8B yen (+7.7%). The company delivered revenue growth combined with margin expansion, as operating margin improved to 8.3% from 7.9% in the prior year period. Despite modest top-line growth in the mid-single digits, operating leverage drove double-digit operating profit growth, reflecting improved cost management. Net income growth of 7.7% lagged operating income growth due to a marginal decline in non-operating profit contribution, though the gap between ordinary and net income remained within normal range. The company maintains a solid financial position with equity ratio of 62.3% and ROE of 12.0%, both exceeding industry median levels.
Revenue increased 5.5B yen or 4.8% YoY to 121.8B yen, driven primarily by the Medical Checkup Solution segment which accounts for 91.0% of total revenue. The Health Management Cloud segment revenue reached 9.4B yen, while Medical Institution Support contributed 1.7B yen. Gross profit margin of 19.0% remained below the 20% threshold, reflecting the company's low-margin business model concentrated in medical checkup solutions where pricing is constrained. Cost of sales increased 4.2% to 98.7B yen, slightly below revenue growth, enabling gross profit to expand 6.6% to 23.1B yen. SG&A expenses rose 7.4% to 13.0B yen, representing 10.6% of revenue, up from 10.4% in the prior period, suggesting incremental investment in selling and administrative functions. The combination of revenue growth and controlled cost increases drove operating income up 10.3% to 10.1B yen, with operating margin improving 0.4pt to 8.3%. Non-operating items resulted in a net expense of 0.2B yen, primarily from other non-operating expenses, causing ordinary income to increase 8.3% to 9.9B yen. Income tax expense of 3.1B yen yielded an effective tax rate of 31.3%, within the normal range. No material extraordinary items or impairments were disclosed. The performance pattern is revenue up, profit up, with operating leverage driving margin expansion despite modest top-line growth.
Health Management Cloud segment generated revenue of 9.4B yen with operating income of 5.1B yen, delivering an exceptional operating margin of 54.2%. This high-margin, cloud-based software business demonstrates strong profitability characteristics. Medical Checkup Solution segment, the company's core business accounting for 91.0% of total revenue, recorded 110.8B yen in sales with operating income of 4.8B yen and a margin of 4.4%. This segment's low margin reflects the service-intensive nature of medical checkup operations where material and labor costs are significant. Medical Institution Support segment contributed 1.7B yen in revenue with operating income of 0.2B yen at a 13.8% margin. The stark margin differential between segments highlights the strategic importance of scaling the Health Management Cloud business, which generates margins more than 12 times higher than the core Medical Checkup Solution segment. Cross-segment performance indicates the company is successfully developing higher-margin digital offerings while maintaining its established medical checkup service base.
[Profitability] ROE 12.0% exceeds the industry median of 8.3%, driven by a net profit margin of 5.6%, total asset turnover of 1.333, and financial leverage of 1.61. Operating margin of 8.3% aligns with the industry median of 8.2%, demonstrating competitive operational efficiency. Gross profit margin of 19.0% remains below the 20% benchmark, reflecting the company's service-based business model with inherent margin constraints. [Cash Quality] Cash and deposits of 52.3B yen provide robust liquidity, covering short-term debt and operational needs with a short-term debt coverage ratio well above 1.0. [Investment Efficiency] Asset turnover of 1.333 significantly exceeds the industry median of 0.67, indicating superior efficiency in generating revenue from assets. Days sales outstanding of 69 days exceeds the industry median of 61 days, reflecting slower receivables collection that warrants attention. [Financial Health] Equity ratio of 62.3% exceeds the industry median of 59.2%, indicating a conservative capital structure. Current ratio of 231.9% significantly surpasses the industry median of 2.15x, demonstrating strong short-term liquidity. Debt-to-equity ratio of 0.61 reflects minimal leverage and ample borrowing capacity for future growth initiatives.
Cash and deposits increased 24.4B yen YoY to 52.3B yen, representing an 87.7% increase that substantially strengthened the company's liquidity position. This significant cash accumulation reflects operating profit growth of 10.3% contributing to cash generation. Trade receivables increased 13.2B yen or 133.1% to 23.2B yen, outpacing revenue growth and indicating extended collection cycles with days sales outstanding reaching 69 days. Trade payables rose 17.3B yen or 174.3% to 27.2B yen, suggesting the company is effectively utilizing supplier credit to finance working capital needs. Inventories increased 1.5B yen or 283.9% to 2.1B yen, though remaining modest as a percentage of total assets given the service-oriented business model. The combination of cash accumulation and working capital expansion suggests operational cash generation is funding both liquidity building and business growth. Total assets increased 39.6B yen to 91.4B yen, with current assets rising 40.4B yen to 78.6B yen, while shareholders' equity grew 22.3B yen to 56.9B yen. Cash coverage of short-term liabilities stands at 1.54 times, indicating ample liquidity to meet obligations. The substantial year-over-year balance sheet growth warrants monitoring to ensure working capital efficiency is maintained as operations scale.
Ordinary income of 9.9B yen versus operating income of 10.1B yen shows a non-operating net expense of approximately 0.2B yen, representing 0.2% of revenue, a minimal impact indicating core operations drive substantially all profitability. Non-operating expenses consist primarily of miscellaneous items without material interest expense, reflecting the company's net cash position and minimal financial leverage. The marginal decline of 0.03B yen in non-operating income from the prior period has limited impact on overall profitability. Profit before tax of 9.9B yen converted to net income of 6.8B yen after income tax expense of 3.1B yen, yielding a tax burden coefficient of 0.687 and effective tax rate of 31.3%, both within normal ranges without indication of unusual tax factors. Operating income to revenue ratio of 8.3% improved from 7.9% YoY, demonstrating genuine operational improvement rather than non-recurring gains. The absence of disclosed extraordinary items or restructuring charges supports sustainable earnings quality. However, the significant increase in trade receivables growing faster than revenue, combined with days sales outstanding of 69 days, raises questions about the timing of cash realization from reported profits. While cash and deposits increased substantially, the lack of disclosed cash flow statement data prevents direct verification that operating cash flow exceeded net income, which would confirm high-quality, cash-backed earnings.
Progress against full-year guidance shows revenue at 121.8B yen representing 82.4% of the 147.9B yen forecast, operating income at 10.1B yen achieving 81.5% of the 12.4B yen target, and net income at 6.8B yen reaching 79.1% of the 8.6B yen projection. With Q3 representing the nine-month point or 75% of the fiscal year, all metrics exceed standard progress rates, indicating performance tracking ahead of the seasonal norm. Revenue progress of 82.4% versus the 75% benchmark suggests a 7.4pt positive variance, while operating income progress of 81.5% reflects a 6.5pt favorable variance. Net income progress of 79.1% shows a 4.1pt positive variance, with all metrics demonstrating above-plan execution. The company revised its dividend forecast upward during the quarter, as noted in the dividend announcement dated February 13, 2026, reflecting confidence in full-year performance and commitment to enhanced shareholder returns. Forecast assumptions include continued growth in the Medical Checkup Solution segment and scaling of the high-margin Health Management Cloud business. The above-plan progress rates suggest the company is well-positioned to meet or potentially exceed full-year guidance, barring unforeseen developments in Q4. The revised dividend forecast indicates management confidence in both earnings visibility and cash generation to support increased distributions.
The company declared a year-end dividend of 42.75 yen per share. The full-year dividend forecast stands at 34.40 yen per share, reflecting the impact of a 2-for-1 stock split effective February 1, 2026. Adjusting for the stock split, the forecasted dividend represents an increase from the prior year, as detailed in the shareholder return policy revision announcement dated February 13, 2026. Based on net income of 6.8B yen and average shares outstanding of 11,937 thousand, basic EPS of 114.40 yen translates to a calculated payout ratio of 78.1% using the pre-split year-end dividend of 42.75 yen and the Q3 annualized earnings. This elevated payout ratio, approaching 80%, indicates an aggressive distribution policy that leaves limited earnings retention for internal reinvestment or buffer against performance variability. No share buyback activity was disclosed for the current period. The absence of buyback data means the total return ratio equals the dividend payout ratio of 78.1%. The revised upward dividend forecast demonstrates management's commitment to returning capital to shareholders, though the sustainability of this payout level depends on continued earnings growth and cash flow generation. With substantial cash reserves of 52.3B yen and minimal debt, near-term dividend coverage appears secure, though the high payout ratio limits financial flexibility for acquisitions or unexpected operational needs.
Margin pressure from low gross profit margin of 19.0%, below the 20% benchmark, constrains profitability improvement and leaves limited buffer to absorb cost increases or pricing pressure in the core Medical Checkup Solution segment which generates 91% of revenue at just 4.4% operating margin. Working capital deterioration evidenced by trade receivables increasing 133.1% YoY far exceeding the 4.8% revenue growth, with days sales outstanding extended to 69 days versus 61-day industry median, creating potential cash flow pressure and elevated bad debt risk if collection discipline is not restored. Dividend sustainability concerns arising from 78.1% payout ratio leaving minimal retained earnings for reinvestment, with full-year dividend forecast of 34.40 yen per share requiring 8.6B yen net income to maintain current distribution level, making the dividend vulnerable to any earnings shortfall despite current strong cash position of 52.3B yen.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 12.0% exceeds industry median of 8.3%, ranking in the upper quartile and demonstrating superior capital efficiency driven by above-median asset turnover of 1.333 versus industry median of 0.67. Operating margin of 8.3% aligns with industry median of 8.2%, while net profit margin of 5.6% falls below the industry median of 6.0%, suggesting slightly higher tax burden or non-operating expenses relative to peers.
Financial Health: Equity ratio of 62.3% exceeds industry median of 59.2%, reflecting a conservative capital structure with room for strategic leverage if needed. Current ratio of 231.9% significantly surpasses industry median of 2.15x, indicating superior liquidity though potentially excess cash that could be deployed more productively.
Efficiency: Asset turnover of 1.333 substantially exceeds industry median of 0.67, ranking the company among the most efficient revenue generators in the IT and Telecom sector. However, receivables turnover of 69 days exceeds the industry median of 61 days, indicating slower collection than peers and representing a relative efficiency weakness.
Growth: Revenue growth of 4.8% YoY trails the industry median of 10.4%, placing the company in the lower half of sector growth rates and suggesting market share challenges or mature market conditions in core medical checkup services.
(Industry: IT and Telecom (n=104 companies), Period: 2025-Q3, Source: Proprietary analysis)
Operating leverage driving margin expansion: The company demonstrated ability to convert modest 4.8% revenue growth into 10.3% operating income growth, with operating margin improving 0.4pt to 8.3%, indicating effective cost management and scale benefits that should continue as revenue grows, particularly as the high-margin Health Management Cloud segment scales from its current 7.7% revenue contribution.
Strategic positioning in digital health transformation: The stark margin differential between the Health Management Cloud segment at 54.2% operating margin versus the legacy Medical Checkup Solution at 4.4% margin highlights the transformation opportunity, with the digital cloud business demonstrating software economics that could materially improve consolidated profitability as this segment grows and cross-selling to the established medical checkup customer base progresses.
Working capital management requiring attention: Trade receivables growth of 133.1% vastly exceeding revenue growth of 4.8%, combined with days sales outstanding of 69 days versus industry median of 61 days, signals deteriorating collection efficiency that, if not addressed, could pressure cash conversion despite strong reported earnings, while the simultaneous 174.3% increase in trade payables suggests reliance on extended supplier credit to fund working capital expansion.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.